KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management.

Hoa Q Nguyen, Ryan L Crass, Sunny Chapel, Han-Yi Steve Kuan, Gordon Loewen, Satjit Brar

J Clin Pharmacol 65(12) 1777-1788

PMID40796529
PMCIDPMC12649288
DOI10.1002/jcph.70092
发表日期2025-08-12
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

Valbenazine improved chorea in individuals with Huntington's disease compared to placebo in a phase 3, placebo-controlled study (KINECT-HD). Population pharmacokinetics (PK) and exposure-response (E-R) analyses focused on understanding the PK characteristics of valbenazine and its active metabolite, [+]-α-dihydrotetrabenazine ([+]-α-HTBZ), and their correlation with clinical efficacy measured by the total maximal chorea (TMC) score. Consistent with previous analyses, a two-compartmental population PK model adequately described valbenazine and [+]-α-HTBZ plasma disposition, generating reliable individual-predicted exposure levels for sequential E-R analysis. The distributions of individual-predicted steady-state exposures of valbenazine and [+]-α-HTBZ were found to largely overlap between patients with tardive dyskinesia and those with Huntington's disease (HD) chorea. The relationship between the change from baseline in TMC score and [+]-α-HTBZ systemic exposure were effectively characterized by a nonlinear Emax model, with negligible impact from selected covariates. The predicted E-R curve closely aligns with the observed data, exhibiting a negative slope that indicates an increasing clinical response with escalating doses of 40, 60, and 80 mg/day. Predicted efficacy appears to reach a plateau at 80 mg once daily (QD), suggesting minimal additional benefit beyond this dosage. Together, results from the population PK model and E-R analyses reinforce the evidence base for valbenazine efficacy in reducing chorea severity, as demonstrated by the notable decrease in TMC scores compared to baseline. They also endorse the selection of dosing regimens ranging from 40 to 80 mg QD for the treatment of chorea in patients with HD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Visual predictive checks for valbenazine and [+]‐α‐HTBZ in patient population with HD chorea. The shaded regions represent 90% confidence intervals of the simulated percentiles (cyan: 5th and 95th percentiles; orange: 50th percentile). The solid black lines represent the median of the observed data, and the dashed black lines represent the 5th and 95th percentiles of the observed data. Open circles represent the prediction‐corrected concentration of valbenazine (left) and [+]‐α‐HTBZ (right), respectively.
非 KM Figure
Figure 2Figure 2 Individual steady‐state AUC 24 of valbenazine (left) and [+]‐α‐HTBZ (right) versus subject types.
非 KM Figure
Figure 3Figure 3 Visual predictive checks of the final E–R model for TMC score change from baseline (a) and daily AUC of [+]‐α‐HTBZ (b). The shaded regions represent 90% confidence intervals (CIs) of the simulated percentiles (purple: 5th and 95th percentiles; pink: 50th percentile). The solid black lines represent the 50th percentiles of the observed data, and the dashed black lines represent the 5th and 95th percentiles of the observed data. Open circles represent the observed change from baseline (CFB) in TMC scores.
非 KM Figure
Figure 4Figure 4 Observed and predicted relationship of change from baseline in TMC score with [+]‐α‐HTBZ exposure. The median and 90% PI of predicted responses are illustrated as a black line and olive shade. Circles are observed data, squares show mean data points with 95% CI error bars at quantiles of AUC values (N ≈66/bin). The boxplots represent medians and interquartile range (IQR) of predicted [+]‐α‐HTBZ exposure at each dose level in the KINECT‐HD study. Lower and upper boundaries of the box represent the 1st quartile (Q1) and 3rd quartile (Q3), respectively; median is shown as a vertical line inside the box; whiskers represent minimum and maximum values that are within 1.5× the IQR below Q1 and above Q3, respectively.
非 KM Figure